PMID- 18176935
OWN - NLM
STAT- MEDLINE
DCOM- 20080904
LR  - 20181113
IS  - 1098-2744 (Electronic)
IS  - 0899-1987 (Print)
IS  - 0899-1987 (Linking)
VI  - 47
IP  - 9
DP  - 2008 Sep
TI  - Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome 
      in breast, ovarian, and pancreatic cancers.
PG  - 701-6
LID - 10.1002/mc.20413 [doi]
AB  - Methylation of lysine 27 on histone H3 (H3K27) by the EZH2 complex is an 
      epigenetic mark that mediates gene silencing. EZH2 is overexpressed in many 
      cancers and correlates with poor prognosis in both breast and prostate cancers. 
      However, the status of H3K27 methylation and its clinical implication in cancer 
      patients have not been reported. We thus examined trimethylation of H3K27 
      (H3K27me3) by immunohistochemistry and its association with clinical variables 
      and prognosis in breast, ovarian, and pancreatic cancers. We found that H3K27me3 
      expression was significantly lower in breast, ovarian and pancreatic cancers than 
      in normal tissues (62% in breast cancer vs. 88% in normal breast tissue, P = 
      0.001; 38.4% in ovarian cancer vs. 83.3% in normal ovarian tissue, P < 0.05; and 
      26% in pancreatic cancer vs. 89% in normal pancreatic tissue, P < 0.001). 
      H3K27me3 expression showed significant prognostic impact in breast, ovarian and 
      pancreatic cancers in univariate survival analyses. In all three cancer types, 
      patients with low expression of H3K27me3 had significantly shorter overall 
      survival time when compared with those with high H3K27me3 expression. In a 
      multivariate model, H3K27me3 expression was an independent prognostic value for 
      overall survival in all three cancer types. These results suggest that H3K27me3 
      expression is a prognostic indicator for clinical outcome in patients with 
      breast, ovarian, and pancreatic cancers.
FAU - Wei, Yongkun
AU  - Wei Y
AD  - Department of Molecular and Cellular Oncology, The University of Texas M.D. 
      Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Xia, Weiya
AU  - Xia W
FAU - Zhang, Zhihong
AU  - Zhang Z
FAU - Liu, Jinsong
AU  - Liu J
FAU - Wang, Huamin
AU  - Wang H
FAU - Adsay, Nazmi V
AU  - Adsay NV
FAU - Albarracin, Constance
AU  - Albarracin C
FAU - Yu, Dihua
AU  - Yu D
FAU - Abbruzzese, James L
AU  - Abbruzzese JL
FAU - Mills, Gordon B
AU  - Mills GB
FAU - Bast, Robert C Jr
AU  - Bast RC Jr
FAU - Hortobagyi, Gabriel N
AU  - Hortobagyi GN
FAU - Hung, Mien-Chie
AU  - Hung MC
LA  - eng
GR  - P50 CA83639/CA/NCI NIH HHS/United States
GR  - R01 CA109311/CA/NCI NIH HHS/United States
GR  - P50 CA083639-050003/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - CA116199/CA/NCI NIH HHS/United States
GR  - CA16672/CA/NCI NIH HHS/United States
GR  - P50 CA116199-04/CA/NCI NIH HHS/United States
GR  - P50 CA116199/CA/NCI NIH HHS/United States
GR  - P20 CA101936/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
GR  - P01 CA099031-05/CA/NCI NIH HHS/United States
GR  - P01 CA099031/CA/NCI NIH HHS/United States
GR  - P20 CA101936-010001/CA/NCI NIH HHS/United States
GR  - R01 CA109311-05/CA/NCI NIH HHS/United States
GR  - P01 CA099031-010001/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Carcinog
JT  - Molecular carcinogenesis
JID - 8811105
RN  - 0 (Histones)
RN  - 3YGF0495O2 (trimethyllysine)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*metabolism/pathology
MH  - Female
MH  - Histones/chemistry/*metabolism
MH  - Humans
MH  - Lysine/*analogs & derivatives/metabolism
MH  - Middle Aged
MH  - Ovarian Neoplasms/*metabolism/pathology
MH  - Pancreatic Neoplasms/*metabolism/pathology
MH  - Predictive Value of Tests
MH  - *Prognosis
MH  - Treatment Failure
MH  - Treatment Outcome
PMC - PMC2580832
MID - NIHMS76157
EDAT- 2008/01/08 09:00
MHDA- 2008/09/05 09:00
PMCR- 2008/11/07
CRDT- 2008/01/08 09:00
PHST- 2008/01/08 09:00 [pubmed]
PHST- 2008/09/05 09:00 [medline]
PHST- 2008/01/08 09:00 [entrez]
PHST- 2008/11/07 00:00 [pmc-release]
AID - 10.1002/mc.20413 [doi]
PST - ppublish
SO  - Mol Carcinog. 2008 Sep;47(9):701-6. doi: 10.1002/mc.20413.